Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of Interest: Thomas Bahmer reports grants from BMBF: Unrestricted research grant for the German Center for Lung Research (DZL), BMBF: National Pandemic Cohort Network (NAPKON) – Coordinating Study Site for population-based cohort platform; lecture fees from Novartis, AstraZeneca, Chiesi; support for attending ATS Congress from Chiesi; advisory board participation at GlaxoSmithKline, Boehringer Ingelheim, Roche, AstraZeneca; outside the submitted work.

Conflict of Interest: Derk Frank reports grants from DFG (467267736), BMBF, DZHK; consulting fees and support for attending meetings from Edwards Lifesciences, Medtronic; lecture honoraria from Edwards Lifesciences, Medtronic, Astra Zeneca, Pfizer, BMS, Novartis, Bayer, Abbott; participation on advisory boards at BMS, Boehringer Ingelheim, Daiichi Sankyo; outside the submitted work.

Conflict of Interest: CellTrend is owned by Kai Schulze-Forster. CellTrend is producing ELISA kits for the determination of Antibodies against GPCR.

Conflict of Interest: Avi Z. Rosenberg reports grants from NIH (NIDDK, NHLBI); outside the submitted work.

Conflict of Interest: Gabriela Riemekasten reports consulting fees from CellTrand GmbH; outside the submitted work.

Conflict of Interest: Stefan Schreiber reports consulting fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Prevention Bio, Protagonist, Falk; outside the submitted work.

Conflict of Interest: All other authors have nothing to disclose.